The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

Novo Nordisk’s share price plunged the most since December after another disappointment for the drugmaker’s next-generation shot CagriSema. The medicine helped patients with diabetes lose 15 ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.

Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy.

Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...